Application of Atelocollagen-mediated siRNA Delivery for RNAi Therapies

DOI Web Site Web Site 3 Citations 33 References
  • HONMA Kimi
    Section for Studies on Metastasis, National Cancer Center Research Institute Koken Bioscience Inst., KOKEN Co., Ltd.
  • TAKESHITA Fumitaka
    Section for Studies on Metastasis, National Cancer Center Research Institute
  • OCHIYA Takahiro
    Section for Studies on Metastasis, National Cancer Center Research Institute

Bibliographic Information

Other Title
  • アテロコラーゲンsiRNA導入技術のRNAi医薬への応用
  • アテロコラーゲン siRNA ドウニュウ ギジュツ ノ RNAi イヤク エノ オウヨウ

Search this article

Abstract

  RNAi has rapidly become a powerful tool for drug target discovery and validation in an in vitro culture system and, consequently, interest is rapidly growing for extension of its application to in vivo systems, such as animal disease models and human therapeutics. Novel treatments and drug discovery in pre-clinical studies based on RNAi are currently targeting a wide range of diseases, including viral infections and cancers by the local administration of synthetic small interfering RNA (siRNA) that target local lesions. Recently, specific methods for the systemic administration of siRNAs have been reported to treat non-human primates or a cancer metastasis model. In vivo siRNA-delivery technology is a key hurdle to the successful therapeutic application of RNAi. This article reviews the non-viral delivery system of atelocollagen for siRNA, which could be useful for functional screening of the genes in vitro and in vivo, and will provide a foundation for further development of RNAi therapeutics.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 127 (5), 807-812, 2007-05-01

    The Pharmaceutical Society of Japan

Citations (3)*help

See more

References(33)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top